Search Within

Heiko Schoder

  1. "Yelena Janjigian"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (7)
Groups
  1. Department of Medicine (16)
  2. Gastrointestinal Oncology Service (16)
  3. Molecular Imaging and Therapy Service (16)
  4. Radiology, Department of (16)
  5. Solid Tumor Oncology Division (16)
  6. Center for Pancreatic Cancer Research (14)

More Groups

People
  1. Yelena Janjigian (16)
  2. Daniel Coit (8)
  3. Laura Tang (8)
  4. Marinela Capanu (8)
  5. Vivian Strong (8)
  6. Geoffrey Ku (7)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (2)
  4. 2021 (1)
  5. 2019 (1)
  6. 2018 (2)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Journal of Nuclear Medicine (3)
  3. Annals of Surgery (1)
  4. Annals of Surgical Oncology (1)
  5. British Journal of Cancer (1)
  6. Cancer Discovery (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. Society of Nuclear Medicine (3)
  3. Elsevier Inc. (2)
  4. Springer (2)
  5. American Association for Cancer Research (1)
  6. Lippincott Williams & Wilkins (1)

More Publishers

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PET-CT-based host metabolic (PETMet) features are associated with pathologic response in gastroesophageal adenocarcinoma
    Journal Article

    White, C.; Jayaprakasam, V. S.; Tenet, M.; Tang, L. H.; Schattner, M. A.; Janjigian, Y. Y.; Maron, S. B.; Schöder, H.; Larson, S. M.; Gönen, M.; more...
    European Journal of Surgical Oncology (2025)

    Fulltext@MSK | Save
  • Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using (18)F-BMS-986229 PET
    Meeting Abstract

    Cytryn, S. L.; Pandit-Taskar, N.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Feder, L.; Philemond, S.; Lyashchenko, S. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • (18)F-BMS-986229 PET to assess programmed-death ligand 1 status in gastroesophageal cancer
    Journal Article

    Cytryn, S. L.; Pandit-Taskar, N.; Lumish, M. A.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Antoine, A.; Loegel, D.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Patient metabolic profile defined by liver and muscle (18)F-FDG PET avidity is independently associated with overall survival in gastric cancer
    Journal Article

    Vitiello, G. A.; Jayaprakasam, V. S.; Tang, L. H.; Schattner, M. A.; Janjigian, Y. Y.; Ku, G. Y.; Maron, S. B.; Schoder, H.; Larson, S. M.; Gönen, M.; more...
    Gastric Cancer (2024)

    Fulltext@MSK | Save
  • Patient metabolic profiles defined by liver and muscle 18F-FDG PET avidity are independently associated with overall survival in gastric cancer
    Meeting Abstract

    Vitiello, G. A.; Jayaprakasam, V. S.; Tang, L.; Schattner, M.; Janjigian, Y.; Ku, G.; Maron, S.; Schoder, H.; Larson, S.; Gonen, M.; more...
    Annals of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: A pilot study
    Journal Article

    Lumish, M. A.; Maron, S. B.; Paroder, V.; Chou, J. F.; Capanu, M.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Lyashchenko, S. K.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Imaging HER2-positive metastatic esophagogastric cancer with (89)Zr-trastuzumab PET and (18)F-FDG PET
    Meeting Abstract

    Lumish, M. A.; Maron, S. B.; Paroder, V.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Janjigian, Y. Y.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer
    Journal Article

    Sanchez-Vega, F.; Hechtman, J. F.; Castel, P.; Ku, G. Y.; Tuvy, Y.; Won, H.; Fong, C. J.; Bouvier, N.; Nanjangud, G. J.; Soong, J.; more...
    Cancer Discovery (2019)

    Fulltext@MSK | Save
  • Post-treatment/pre-operative PET response is not an independent predictor of outcomes for patients with gastric and GEJ adenocarcinoma
    Journal Article

    Hernandez, J. M.; Beylergil, V.; Goldman, D. A.; van Beek, E.; Gonen, M.; Tang, L.; Downey, R.; Rizk, N.; Shah, M.; Strong, V.; more...
    Annals of Surgery (2018)

    Fulltext@MSK | Save
  • Pharmacokinetics, biodistribution, and radiation dosimetry for (89)Zr-trastuzumab in patients with esophagogastric cancer
    Journal Article

    O'Donoghue, J. A.; Lewis, J. S.; Pandit-Taskar, N.; Fleming, S. E.; Schöder, H.; Larson, S. M.; Beylergil, V.; Ruan, S.; Lyashchenko, S. K.; Zanzonico, P. B.; more...
    Journal of Nuclear Medicine (2018)

    Fulltext@MSK | Save